Follicular and Hürthle Cell Carcinoma of the Thyroid Gland

Surgical Oncology Clinics of North America

Volumn 15, Issue 3, 2006, Pages 603-623

  Phitayakorn, Roy ^a   McHenry, Christopher R ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; HUMAN; HURTHLE CELL CARCINOMA; INFERTILITY; LYMPH NODE METASTASIS; METASTASIS; NAUSEA; NEEDLE BIOPSY; REVIEW; SIALOADENITIS; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADENOMA; ADENOMA, OXYPHILIC; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 33746381526     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.05.011     Document Type: Review

References (92)

1. Johnson T.L., Lloyd R.V., Burney R.E., et al. Hürthle cell thyroid tumors: an immunohistochemical study. Cancer 59 (1987) 107-112
2. Clark O.H., and Gerend P.L. Thyrotropin receptor-adenylate cyclase system in Hürthle cell neoplasms. J Clin Endocrinol Metab 61 (1985) 773-778
3. Bondeson L., Bondeson A.G., Ljungberg O., et al. Oxyphil tumors of the thyroid: follow-up of 42 surgical cases. Ann Surg 194 (1981) 677-680
4. Lopez-Penabad L., Chiu A.C., Hoff A.O., et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer 97 5 (2003) 1186-1194
5. Soh E.Y., and Clark O.H. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 25 (1996) 115-139
6. Maxon H.R., and Smith H.S. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 19 (1990) 685-718
7. Rosai J., Carcangiu M.L., and De Lellis R.A. Tumors of the thyroid gland. In: Rosai J., and Sobin L.H. (Eds). Atlas of tumor pathology. 3rd series, fascicle 5 (1992), Armed Forces Institute of Pathology, Washington (DC) 49-62 161-179
8. Correra P., and Chen V.W. Endocrine gland cancer. Cancer 75 suppl (1995) 338-352
9. LiVolsi V. The demise of follicular carcinoma of the thyroid gland. Thyroid 4 (1994) 233-236
10. Wu H.S., Young M.T., Ituarte P.H., et al. Death from thyroid cancer of follicular cell origin. J Am Coll Surg 191 6 (2000) 600-606
11. Van Heerden J.A., Hay I.D., Goellner J.R., et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112 (1992) 1130-1138
12. Sanders L.E., and Silverman M. Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery 124 (1998) 967-974
13. Franssila K.O., Ackerman L.V., Brown C.L., et al. Follicular carcinoma. Semin Diagn Pathol 2 2 (1985) 101-122
14. Shaha A.R., Shah J.P., and Loree T.R. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 172 (1997) 692-694
15. Lo C.Y., Chan W.F., Lam K.Y., et al. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg 242 (2005) 708-715
16. DeGroot L.J., Kaplan E.L., Shukla M.S., et al. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80 (1995) 2946-2953
17. Martins R.G., Caplan H.R., Lamber P.J., et al. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. J Am Coll Surg 185 (1997) 388-397
18. Schelfhout L.J., Creutzberg C.L., Hamming J.F., et al. Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol 24 (1988) 331-337
19. Chow S.M., Law S.C., Mendenhall W.M., et al. Follicular thyroid carcinoma: prognostic factors and the role of radioiodine. Cancer 95 3 (2002) 488-498
20. Witte J., Goretzki P.E., Dieken J., et al. Importance of lymph node metastases in follicular thyroid cancer. World J Surg 26 (2002) 1017-1022
21. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 128 1 (2003) 115-123
22. Lin J.D., Chao T.C., and Hsueh C. Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study. Endocr J 51 2 (2004) 219-225
23. Machens A., Holzhausen H.J., and Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103 11 (2005) 2269-2273
24. Sobrino S.M., Asa S.L., Krdl T.G., et al. Follicular carcinoma. In: DeLellis R.A., Lloyd R.V., Heitz P.U., and Eng C. (Eds). WHO classification of tumors: pathology and genetics: tumors of endocrine organs (2004), IARC Press, Lyon (France) 67-76
25. Ewing J. Neoplastic diseases. 2nd edition (1928), Saunders, Philadelphia (PA) p. 952-3
26. Hundahl S.A., Fleming I.D., Frengen A.M., et al. A National Cancer Data Base report in 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83 (1998) 2638-2648
27. Talini G., Carcangiu M.L., and Rosai J. Oncocytic neoplasms of the thyroid gland. Acta Pathol Jpn 42 (1992) 305-315
28. Ruegemer J.J., Hay I.D., Bergstralth E.J., et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variable. J Clin Endocrinol Metab 67 (1988) 501-508
29. Grossman R.F., and Clark O.H. Hürthle cell carcinoma. Cancer Control 4 (1997) 13-17
30. Finley D.J., Zhu B., and Fahey T.J. Molecular analysis of Hürthle cell neoplasms by gene profiling. Surgery 136 (2004) 1160-1168
31. Haigh P.I., and Urbach D.R. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery 138 6 (2005) 1152-1157
32. Stojadinovic A., Ghossein R.A., Hoos A., et al. Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 19 10 (2001) 2616-2625
33. McHenry C.R., and Sandoval B.A. Management of follicular and Hürthle cell neoplasms of the thyroid gland. Surg Oncol Clin N Am 7 4 (1998) 893-910
34. McHenry C.R., Raeburn C., Strickland T., et al. The utility of frozen section examination for intraoperative diagnosis of thyroid cancer. Am J Surg 172 (1996) 658-661
35. Alaedeen D.I., Khiyami A., and McHenry C.R. Fine needle aspiration biopsy specimens with a predominance of Hürthle cell: a dilemma in the management of nodular thyroid disease. Surgery 138 (2005) 650-657
36. De Jong S.A., Demeter J.G., and Castelli M. Follicular cell predominance in the cytologic examination of dominant thyroid nodules indicates a sixty percent incidence of neoplasm. Surgery 108 (1990) 794-799
37. Gundry S.R., Burney R.E., Thompson N.W., et al. Total thyroidectomy for Hürthle cell neoplasms of the thyroid. Arch Surg 118 (1983) 529-532
38. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289 (2000) 1357-1360
39. Ying H., Suzuki H., Zhao L., et al. Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferators-activated receptor γ during thyroid carcinogenesis. Canc Res 63 (2003) 5274-5280
40. Weber F., Shen L., Aldred M.A., et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90 (2005) 2512-2521
41. Challeton C., Bounacer A., Du Villard J.A., et al. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 11 (1995) 601-603
42. Lewinski A., Ferenc T., Sporny S., et al. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background. Endocr Regul 34 (2000) 99-113
43. Hermann M.E., Talpos G.B., Mohamed A.N., et al. Genetic markers in thyroid tumors. Surgery 110 (1991) 941-948
44. Chinnapa P., Taguba L., Arciaga R., et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 89 (2004) 3705-3709
45. Sato T., Harao M., Nakano S., et al. Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Surgery 137 (2005) 552-558
46. Duh Q.Y. What's new in general surgery: endocrine surgery. J Am Coll Surg 201 5 (2005) 746-753
47. Chen H., Nicol T.L., and Udelsman R. Follicular lesions of the thyroid: does frozen section evaluation alter operative management?. Ann Surg 222 (1995) 101
48. Shaha A.R., DiMaio T., Webber C., et al. Intraoperative decision making during thyroid surgery based on the results of preoperative needle biopsy and frozen section exam. Surgery 108 6 (1990) 964
49. Stojadinovic A., Hoos A., Ghossein R.A., et al. Hürthle cell carcinoma: a 60-year experience. Ann Surg Oncol 9 (2002) 197-203
50. Arganini M., Behar R., Wu T., et al. Hürthle cell tumors: a twenty-five-year experience. Surgery 100 (1986) 1108-1115
51. Hoos A., Stojadinovic A., Singh B., et al. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 160 1 (2002) 175-183
52. Mazzaferri E.L., and Kloos R.T. Using recombinant human TSH in the management of well differentiated thyroid cancer: current strategies and future directions. Thyroid 10 9 (2000) 767-778
53. Morris L.F., Wilder M.S., Waxman A.D., et al. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid 11 (2001) 749-755
54. Burmeister L.A. Thyroid hormone in the treatment of thyroid cancer. Thyroid Today 17 (1994) 1-9
55. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 5 (1994) 418-428
56. Schlumberger M., Mancusi F., Baudin E., et al. I-131 therapy for elevated thyroglobulin levels. Thyroid 7 (1997) 273-276
57. Cailleux A.F., Baudin E., Travagli J.P., et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 85 (2000) 175-178
58. Brierley J., and Maxon H.R. Radioiodine and external radiation therapy. In: Fagin J.A. (Ed). Thyroid cancer (1998), Kluwer Academic Publishers, London 285-317
59. McHenry C.R., Jarosz H., Davis M., et al. Selective postoperative radioactive iodine treatment of thyroid carcinoma. Surgery 106 (1989) 956-959
60. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the state of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (2005) 1407-1427
61. Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37 (1996) 598-605
62. Hyer S., Vini L., O'Connell M., et al. Testicular dose and fertility in men following I-131 therapy for thyroid cancer. Clin Endocrinol (Oxf) 56 (2002) 755-758
63. Vini L., Hyer S., Al-Saadi A., et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 78 (2002) 92-93
64. Schlumberger M., De Vathaire F., Ceccarelli C., et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37 (1996) 606-612
65. Ceccarelli C., Bencivelli W., Morciano D., et al. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 86 (2001) 3512-3515
66. Hocevar M., Auersperg M., and Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after surgery. Eur J Surg Oncol 23 (1997) 208-210
67. Torrens J.I., and Burch H.B. Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 30 2 (2001) 429-467
68. Haugen B.R., and Lin E.C. Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am 30 (2001) 469-492
69. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79 (1994) 98-105
70. Pacini F., Capezzone M., and Elisei R. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87 4 (2002) 1499-1501
71. Spencer C.A., Takeuchi M., Kazarosyan M., et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83 (1998) 1121-1127
72. Savagner F., Rodien P., Reynier P., et al. Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients. J Clin Endocrinol Metab 87 (2002) 635-639
73. Bellantone R., Lombardi C.P., Bossola M., et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. Cancer 92 (2001) 2273-2279
74. Frilling A., Tecklenborg K., Gorges R., et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234 (2001) 804-811
75. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]-Fluro-2-deoxy-D-glucose positron emission tomography scanning. J Clin Endocrinol Metab 91 (2006) 498-505
76. Lowe V.J., Mullan B.P., Hay I.D., et al. 18F-FDGPET of patients with Hürthle cell carcinoma. J Nucl Med 44 (2003) 1402-1406
77. Pineda J.D., Lee T., Ain K., Reynolds J., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80 (1995) 1488-1492
78. American Joint Committee on Cancer. AJCC cancer staging manual: thyroid cancer (2002), Springer-Verlag, Berlin
79. Shaha A.R., Shah J.P., and Loree T.R. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174 (1997) 474-476
80. Kushchayeva Y., Duh Q.Y., Kebebew E., et al. Prognostic indications for Hürthle cell cancer. World J Surg 28 (2004) 1266-1270
81. Schlumberger M., Tubiana M., De Vathaire F., et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63 4 (1986) 960-967
82. Kitamura Y., Shimizu K., Nagahama M., et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 84 (1999) 4043-4049
83. Har-El G., Hadar T., Segal K., et al. Hürthle cell carcinoma of the thyroid gland: a tumor of moderate malignancy. Cancer 57 (1986) 1613-1617
84. Ryan J.L., Hay I.D., Grant C.S., et al. Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid. World J Surg 12 (1988) 482-487
85. Khafif A., Khafif R., and Attie J.N. Hürthle cell carcinoma: a malignancy of low-grade potential. Head Neck 21 6 (1999) 506-511
86. Dahl L.D., Myssiorek D., and Heller K.S. Hürthle cell neoplasms of the thyroid. Laryngoscope 112 (2002) 2178-2180
87. Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck 129 (2003) 207-210
88. Mai K.T., Thomas J., Yazdi H.M., et al. Pathologic study and clinical significance of Hürthle cell papillary thyroid carcinoma. Appl Immunohistochem Mol Morphol 12 (2004) 329-337
89. Maxwell E.L., Palme C.E., and Freeman J. Hürthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck 132 (2006) 54-58
90. Tzavara I., Vlassopoulou B., Alevizak C., et al. Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece. Clin Endocrinol (Oxf) 50 (1999) 643-654
91. Steinmüller T., Klupp J., Rayes N., et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg 166 (2000) 29-33
92. Tsang R.W., Brierley J.D., and Simpson W.J. The effects of surgery, radioiodine, and eternal radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82 (1998) 375-388